Pharmaxis (ASX: PXS) today announced that it had filed a minor resubmission with the Pharmaceutical Benefits Advisory Committee (PBAC) for its new drug Bronchitol for the treatment of cystic fibrosis.  The submission will be considered at the Committee’s next meeting scheduled to take place in March 2012. A recommendation by PBAC is required for listing on the Australian Pharmaceutical Benefits Scheme (PBS).

Read Media Release